Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Brooklyn ImmunoTherapeutics Inc. BTX

Brooklyn ImmunoTherapeutics Inc is a clinical-stage biopharmaceutical company. It is developing IRX-2, a novel hd-IL-2 -based therapy, to treat patients with cancer. IRX-2 delivers hd-IL-2 and other key cytokines to potentially restore immune function in the tumor microenvironment, enabling the immune system to attack cancer cells.

Recent & Breaking News (NDAQ:BTX)

Brooklyn ImmunoTherapeutics Announces Results of Phase 2 Study of IRX-2 in Head and Neck Cancer

GlobeNewswire July 26, 2022

Brooklyn ImmunoTherapeutics Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

GlobeNewswire June 17, 2022

Brooklyn ImmunoTherapeutics Announces Board Changes

GlobeNewswire June 7, 2022

Brooklyn ImmunoTherapeutics Announces Changes to Executive Management: Matt Angel, Ph.D. Appointed Interim Chief Executive Officer and President, Andrew Jackson Appointed Chief Financial Officer Postpones 2022 Annual Meeting

GlobeNewswire May 31, 2022

Brooklyn ImmunoTherapeutics Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Quarterly Report on Form 10-Q

GlobeNewswire May 27, 2022

Amarin Announces Appointment of New Directors and Board Leadership Changes

GlobeNewswire May 19, 2022

Brooklyn ImmunoTherapeutics Announces Establishment of New Research and Development Facility for Advancement of Engineered Cellular Medicines

GlobeNewswire April 21, 2022

Brooklyn ImmunoTherapeutics Announces Fourth Quarter and Full Year 2021 Financial Results

GlobeNewswire April 15, 2022

Brooklyn ImmunoTherapeutics Announces Closing of $12 Million Private Placement

GlobeNewswire March 9, 2022

Brooklyn ImmunoTherapeutics Announces $12 Million Private Placement

GlobeNewswire March 7, 2022

Brooklyn ImmunoTherapeutics Welcomes Erin S. Enright and Heather B. Redman to Its Board of Directors

GlobeNewswire January 20, 2022

Brooklyn ImmunoTherapeutics Provides Update on Regenerative Medicine Intellectual Property Portfolio

GlobeNewswire January 13, 2022

Brooklyn ImmunoTherapeutics Added to ICE Biotechnology Index

GlobeNewswire December 17, 2021

Brooklyn ImmunoTherapeutics Named to Nasdaq Biotechnology Index

GlobeNewswire December 14, 2021

Brooklyn ImmunoTherapeutics to Present at Two Upcoming December Conferences

GlobeNewswire December 2, 2021

Brooklyn ImmunoTherapeutics Welcomes Susan McClatchey as Vice President and Head of Quality

GlobeNewswire November 29, 2021

Brooklyn ImmunoTherapeutics Announces Filing of Registration Statement for Proposed Secondary Offering of Shares Issued in Previously Announced Novellus Acquisition

GlobeNewswire November 19, 2021

Brooklyn ImmunoTherapeutics Announces Third Quarter 2021 Financial Results

GlobeNewswire November 9, 2021

Brooklyn ImmunoTherapeutics to Move Stock Exchange Listing to Nasdaq

GlobeNewswire October 14, 2021

Brooklyn ImmunoTherapeutics Reports Inducement Grants

GlobeNewswire September 23, 2021